How to Prepare Overseas Registration Dossiers for IVD Products

Answer at a Glance

The core of preparing an overseas registration dossier for IVD products is to organize technical documentation, quality system evidence, clinical evaluation data, and local-language documents in line with the regulatory framework of the target country. A company should first determine whether the product falls within the medical device or IVD regulatory scope of that country, and then select the registration route based on risk classification. Existing approvals such as China NMPA, EU CE, US FDA, or ISO 13485 documentation can be partially reused, but the company must assess gaps and supplement any locally required performance verification, biological evaluation, stability data, and other evidence.

Purpose and Core Questions

Companies searching for this topic usually need to know whether their existing documentation can support an application in the target market, whether a local agent or authorized representative is required, why timelines are often extended, and which issues can affect launch plans. These concerns involve product classification, registration pathways, evidence chains, label localization, and post-market maintenance obligations.

When entering multiple GHWP member states or Southeast Asian, Middle Eastern, or Latin American markets simultaneously, a single-country explanation is not sufficient. A more effective approach is to first build reusable versions of core technical documentation, quality system certificates, performance verification data, clinical evidence, and labeling, and then localize these documents according to each country's regulatory requirements.

Regulatory Classification and Registration Logic

First, confirm whether the product is regulated as a medical device or IVD in the target country. For example, Saudi Arabia's SFDA has specific classifications for certain reagent kits, while Thailand's TFDA classifies reagents into A, B, C, and D categories. Second, determine the risk level: low-risk products may qualify for self-declaration or simplified registration, while medium- and high-risk products require full technical review. Third, assess the reusability of existing documentation. Products holding an EU IVDR certificate, FDA 510(k) clearance, or NMPA registration can largely reuse their risk management report, performance evaluation report, and clinical evidence, but must supplement locally applicable standard differences—such as China's requirement that clinical evaluations for reagents be based on domestic population data.

Next, confirm applicant eligibility. Most countries require the manufacturer to be a local entity or to appoint an authorized representative such as the EU REP for Europe or a local agent in Saudi Arabia. Finally, plan post-market obligations, including adverse event reporting, change notifications, and periodic updates. These differ by jurisdiction and must be integrated into the quality system before submission.

Documentation and Evidence Requirements

Technical files usually include: product description and intended use; design and development history; risk management report (ISO 14971); performance verification reports (precision, accuracy, sensitivity, specificity, linearity, etc.); stability studies (real-time, accelerated, and transport simulation); biological evaluation where applicable; clinical evaluation reports or clinical trial data (including clinical performance studies or comparative studies); labeling and instructions for use in the original and local languages; and software validation documentation when applicable.

Quality system evidence includes ISO 13485 certification, MDSAP certificate if required by the target country, and a factory master file or quality management system description. Special country-specific documents may also be required: Brazil's ANVISA requires a GMP certificate; Japan's PMDA requires designation of a Marketing Authorization Holder and manufacturing control procedures; India's CDSCO requires clinical performance data generated locally for certain products.

Reusability assessment: performance evaluation reports under the EU IVDR may be referenced by many GHWP member states, but local validation using representative samples is often required. Thailand, for example, may ask for additional testing against locally prevalent subtypes. Therefore, companies should modularize core documents so that country-specific supplements can be efficiently added.

Common Mistakes

The most widespread problem is treating registration as a simple document submission exercise without first clarifying product classification, evidence coverage, and local responsibility relationships.

• Directly translating NMPA documentation without reorganizing evidence according to the target market's pathway.
• Including too many model/type variants while testing reports, clinical evidence, or labeling do not fully cover them.
• Selecting a local agent based only on sales cooperation rather than defining regulatory responsibility, certificate control, and post-market maintenance obligations.
• Having inconsistent claims across labels, instructions, promotional materials, and registration dossiers.
• Failing to plan for multi-country document reuse, which leads to repetitive work and multiplied cost and timeline burdens in every market.

Company Preparation Checklist

• Build a regulatory team that includes regulatory affairs, quality, technical, clinical, and translation staff—or engage a professional contract research organization (CRO).
• Confirm the target country's classification and registration route through official regulatory databases or consultants, including fees and estimated timelines.
• Inventory existing NMPA, CE, FDA, and ISO 13485 certificates and technical documents, and perform a gap analysis against target-country requirements.
• Develop core technical documents—especially risk management, performance verification, stability, and clinical evaluation—ensuring compliance with ISO standards and any relevant national guidance.
• Update quality system documents such as factory master records, nonconformance handling procedures, post-market surveillance plans, and adverse event reporting procedures.
• Localize labels and instructions for use, including language, safety symbols, and units of measurement, as required by local regulation.
• Appoint a local agent or authorized representative in each target country and sign agreements that clearly establish authority and responsibility.
• Submit the application via each country's designated electronic or paper system, prepare to answer deficiency requests, and track review progress.
• Maintain certificates after approval: monitor validity, plan renewals, and manage change notifications.

Additional Common Questions

Is a clinical trial always required for overseas IVD registration?

Not always. Many countries accept clinical performance studies comparing against a legally marketed similar product, or the use of real-world data. For example, under the EU IVDR, Class D products require clinical performance studies, but literature or retrospective data may partly substitute. However, China and Brazil may require local clinical trial data from the target population. A company should evaluate based on product novelty and target-country requirements.

Can a valid CE certificate be directly used for registration in another country?

Technical documentation can be partially reused, but the CE certificate itself cannot be used as a registration approval. Most countries refer to CE processes but perform their own review and issue a local registration certificate. For instance, Southeast Asian countries often require CE files but may demand local stability testing or label translations. Companies still must prepare a complete dossier and appoint a local agent.

Are English-language documents accepted for multiple country registrations?

Core documents such as risk management and performance reports can be submitted in English. However, instructions for use, labels, and application forms must be translated into the official local language, for example Thai, Arabic, or Portuguese. Some countries require notarized or sworn translation. It is advisable to prepare core English templates and contract professional local translation services.

AIMEILI Regulatory Interpretation and Business Impact

Many companies mistakenly believe a single set of documents will work in all markets. In reality, each country has unique details for performance verification, clinical evidence, and labeling. Directly reusing CE files may result in deficiency questions if population-specific data are absent. Before a project begins, a company should conduct regulatory research in the target country, identify critical differences, and then focus resources on developing core documents.

Risk management reports, design history files, and clinical evaluation reports are the three most broadly reusable documents. They should be carefully written with traceability maintained. ISO 13485 and MDSAP certificates can significantly simplify quality system audits, but not all countries recognize them. Companies may still need to provide a local-language summary of the quality manual.

The local agent is not merely a legal requirement but also a communication bridge. AIMEILI advises selecting an agent with proven experience and change-management ability, and clearly defines in the contract who holds control of certificates. For multi-country registration, adopt a core-file-plus-country-appendix structure to reduce repetitive compilation and translation work. In parallel, post-market surveillance reports and periodic update reports should be built into the quality system before they are requested by regulators.

Registration is not a one-time project but a continuous process. Companies are best advised to integrate regulatory compliance into early product development. This will substantially reduce the costs of future supplemental studies and change control. AIMEILI also recommends treating this question as part of a GHWP member state and multi-country market access strategy. By establishing a reusable core technical document system and a country-specific gap list, companies can build repeatable overseas compliance capability and avoid starting from zero in every new market.